BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar
Completed
- Conditions
- Carcinoma, Renal CellCarcinoma, Renal Cell (Advanced)
- Interventions
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2010-09-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2840
- Registration Number
- NCT00895674
BEYOND Pilot Study
Phase 2
Completed
- Conditions
- Multiple SclerosisRelapsing-Remitting
- Interventions
- First Posted Date
- 2009-05-05
- Last Posted Date
- 2009-11-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 71
- Registration Number
- NCT00893217
Comparative Safety Study of New Sinecort Formulation Versus Positive Control
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Device: Untreated skin under application chamberDrug: Positive control, Na-laurylsulfat-solution
- First Posted Date
- 2009-04-22
- Last Posted Date
- 2014-06-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 33
- Registration Number
- NCT00885937
GA Levonorgestrel Intrauterine Contraceptive System (LCS) Phase III Study China
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2014-08-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 918
- Registration Number
- NCT00884260
Mirena Observational Program
Completed
- Conditions
- ContraceptionEndometrial HyperplasiaEstrogen Replacement TherapyMenorrhagia
- Interventions
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2725
- Registration Number
- NCT00883662
Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)
- First Posted Date
- 2009-04-17
- Last Posted Date
- 2009-04-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 38
- Registration Number
- NCT00882947
Physical Activity and Fatigue in Early Multiple Sclerosis (MS)
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2012-05-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1739
- Registration Number
- NCT00882453
SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2014-06-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 345
- Registration Number
- NCT00879008
VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis
Completed
- Conditions
- Chronic BronchitisDisease Exacerbation
- Interventions
- First Posted Date
- 2009-04-06
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1206
- Registration Number
- NCT00876577
PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination
- First Posted Date
- 2009-04-06
- Last Posted Date
- 2011-02-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 44920
- Registration Number
- NCT00876083